Skip to main content

Table 6 Relation of overall survival (OS) and progression-free survival (PFS) to different clinicopathological parameters

From: Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups

  Overall survival (OS) Progression-free survival (PFS)  
  Mean Median % End of study P value Mean Median % End of study P value
Age group (years)         
 < 3 (infants) 18.38 20 50% 0.363 13.75 11 25% 0.182
 3-16 (pediatric age) 18.44 22 44.4% 15.15 17 22.2%
 > 16 (adults) 23.8   80% 22.8   60%
Histopathological types         
 Classic medulloblastoma 21.93#   71.4% < 0.001* 20.5# 22 42.9% 0.001*
 Desmoplastic/nodular medulloblastoma 23.1#   70% 18.7# 20 30%
 Large cell/anaplastic medulloblastoma 14.13 10 18.8% 9.94 8 12.5%
Degree of anaplasia         
 Slight anaplasia 22.86   71.4% 0.274 20.71#   57.1% 0.003*
 Moderate anaplasia 19.53   53.3% 18# 20 40%
 Severe anaplasia 17.28 16 38.9% 12.11 11 5.6%
Molecular Subgroups         
 WNT 24#   100% 0.012* 24   100% 0.005*
 SHH 23.08#   66.7% 18.92# 20 33.3%
 Non-WNT/SHH 16.29 15 33.3%   12.92# 10 12.5%
Risk stratification         
 Standard risk 23.61   83.3% < 0.001* 21.61 23.0 50% < 0.001*
 High risk 15.41 14 22.7% 11.09 9.0 9.1%
  1. OS overall survival
  2. #Statistically significant with large cell/anaplastic medulloblastoma
  3. #Statistically significant with non-WNT/SHH
  4. PFS progression-free survival
  5. #Statistically significant with large cell/anaplastic medulloblastoma
  6. #Statistically significant with severe anaplasia
  7. #Statistically significant with WNT